US EditionWeight-loss drug semaglutide reduces heavy alcohol drinking in new clinical trial
5 Articles
5 Articles
Weight-loss drug semaglutide reduces heavy alcohol drinking in new clinical trial
A recent study finds that the active ingredient in Wegovy and Ozempic significantly decreased heavy drinking in patients with obesity and alcohol use disorder. The findings suggest a potential new treatment path for millions of people.
A study with 108 adults has revealed that a weekly injection of semaglutide -a drug used to treat type 2 diabetes and obesity - reduced the number of days of excessive alcohol consumption. The entry Drugs for obesity reduces the days of excessive alcohol consumption, according to one study it was first published in Digital Process.
What did the Danish study find?
Weight loss drugs may help cut alcohol harm Coverage highlights a Danish study examining whether medications best known for weight loss and diabetes—such as Wegovy, Ozempic, and Mounjaro (GLP 1/GIP linked drugs)—could be repurposed to reduce harmful drinking in people with alcohol use disorder .…
Semaglutide, the active ingredient in the diabetes and obesity medications Ozempic and Wegovy, also appears to be useful for treating people with alcohol addiction, according to a new study. Previous studies had already suggested that the drug can help combat various types of addiction.
Coverage Details
Bias Distribution
- 100% of the sources are Center
Factuality
To view factuality data please Upgrade to Premium
